Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream for Low Risk Nodular Basal Cell Carcinoma
NCT00204555Phase 4Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2002
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of imiquimod in basal cell carcinoma (BCC), sponsored by University Hospital Tübingen. Started Jan 2002; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00204555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204555.